Biocon Limited — Investor Meet, 31-01-2025: Analysts/Institutional Investor Meet/Con. Call Updates

1. **Financial Performance:** Biocon reported operating revenue of ₹3,821 Cr for Q3 FY25, a year-over-year decline of 3%, but a sequential increase of 6%. Biosimilars revenue decreased by 8% YoY to ₹2,289 Cr, while Generics dropped 2% YoY to ₹686 Cr. Research Services saw robust growth with a 10% sequential increase, totaling ₹944 Cr. Core EBITDA rose to ₹1,007 Cr, up from ₹983 Cr YoY, implying a margin contraction to 26%. Net profit before exceptional items was ₹13 Cr, significantly down from ₹644 Cr YoY.

2. **Future Outlook and Growth Drivers:** Management remains optimistic about a shift to growth in H2 FY25, supported by planned launches in Generics, especially a GLP1 generic in key markets. Continued strong momentum is anticipated in Biosimilars, backed by several new product launches.

3. **Order Book and Operational Updates:** The company announced completion of all deferred milestones related to the Viatris acquisition. Regulatory milestones include FDA approvals for critical products and facility certifications with VAI status, positioning the company well for future sales.

4. **Analyst Q&A Insights (Detailed):**

- **Revenue and Profitability:** Analysts sought clarity on revenue projections; management cited growth in Biosimilars and R&D investments as key drivers.

- **Market Position and Competitive Landscape:** Questions around competitive positioning led to insights on market share stability in Europe and growth strategies in the U.S.

- **Operational Challenges or Risks:** Analysts inquired about supply chain and regulatory challenges; management expressed confidence in managing these risks.

- **Capex and Capital Allocation:** Discussions on capital expenditure revealed focus on high-impact projects and market expansions.

- **Strategic Priorities and Long-Term Vision:** Queries regarding sustainability and innovation strategies yielded responses highlighting alignment with market trends.

5. **Market or Regulatory Updates:** Key regulatory achievements include multiple product approvals in major markets, reinforcing Biocon’s strategic position in Biosimilars.

6. **Strategic Focus Areas:** The call emphasized growth through innovation in product offerings and operational efficiency, with a clear focus on strengthening market share.

7. **Investor Insight:** Biocon’s current financial trajectory, along with strong strategic plans, suggests potential for upward movement; views may align with a ‘buy’ perspective as investors weigh growth prospects against recent challenges.